Endorex Corporation Presents Live and Online At the Wells Fargo Van Kasper "Class of 2001" Conference.

Business/Medical Editors

CHICAGO--(BW HealthWire)--Sept. 4, 2001

Endorex Corporation (AMEX:DOR) Endorex Corporation's President and CEO Michael Rosen will present an overview of the Company's drug delivery systems and business strategy live on Wednesday, September 5, 2001 - 9:00 a.m. PDT at the "Class of 2001" conference hosted by Wells Fargo Van Kasper LLC in San Francisco.

Endorex is a development-stage drug delivery company developing oral and mucosal formulations of protein- and peptide-based drugs that are traditionally delivered in an injectable format.

On September 5-6, 2001, the conference will feature concurrent sessions by chief executives from a select group of growth stock companies and private companies. Additionally, Wells Fargo Van Kasper will be simulcasting this conference as a live audio webcast at ON24.com. Over 80 companies across a broad industry range will provide 25-minute presentations of their company story, emphasizing key investment issues and corporate strategy.

Among the topics Mr. Rosen will discuss is the recently announced merger with Corporate Technology Development, Inc. ("CTD"), a privately held development-stage specialty pharmaceutical company based in Miami, Florida, whereby Endorex will acquire CTD in a stock-for-stock merger.

You may access Michael Rosen's presentation at the "Class of 2001" Conference via Endorex's website. Please follow these steps:

Go to www.endorex.com on the Internet

Click the ON24 logo to listen to the live webcast

Minimum software required to listen is Windows Media Player, downloadable free at http://windowsmedia.com/download/download/asp

Endorex is a development-stage drug delivery company developing oral and mucosal formulations of protein- and peptide-based drugs that are traditionally delivered in an injectable format. Endorex anticipates that this alternative delivery system will enhance patient quality of life and potentially reduce the healthcare cost related to needle-based delivery. For further information regarding Endorex, please visit the company's website located at www.endorex.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of known and unknown risks and uncertainties. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our cash expenditures will be at projected levels, that we will be able to obtain future financing or funds, that we or our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our joint ventures or our collaborations with other companies will continue, that our business strategy will be successful, that we will be able to carry out our plans for 2001 and beyond or that the merger will be consummated. In addition to the matters described in this press release, risk factors as described from time to time in Endorex's filings with the Securities and Exchange Commission, including, but not limited to, our most recent reports on Form 10-QSB, Form 10-KSB, as amended, and our Registration Statement on Form S-3, as amended, may affect our financial results. We assume no obligation to update the information in this release.